Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
Olema Pharmaceuticals (Nasdaq: OLMA) has appointed Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary. Mitchell brings 20 years of experience in healthcare, life sciences, and sustainability industries. She previously served as Chief Legal Officer at Genomatica and held executive positions at Zogenix and Aptevo Therapeutics.
Mitchell will lead Olema's Legal function as the company advances its late-stage palazestrant programs and OP-3136 KAT6 program through clinical development. Her expertise spans regulatory, commercial, intellectual property, and business development matters. Mitchell holds a B.S. in Biological Sciences from Stanford University and a J.D. from The George Washington University Law School.
Olema Pharmaceuticals (Nasdaq: OLMA) ha nominato Shawnte M. Mitchell, J.D. come Chief Legal Officer e Corporate Secretary. Mitchell porta con sé 20 anni di esperienza nei settori della sanità, delle scienze della vita e della sostenibilità. In precedenza, ha ricoperto il ruolo di Chief Legal Officer presso Genomatica e ha ricoperto posizioni dirigenziali in Zogenix e Aptevo Therapeutics.
Mitchell guiderà la funzione legale di Olema mentre l'azienda avanza nei suoi programmi tardivi di palazestrant e nel programma OP-3136 KAT6 attraverso lo sviluppo clinico. La sua esperienza comprende questioni relative a regolamentazione, commerciale, proprietà intellettuale e sviluppo aziendale. Mitchell ha conseguito una laurea in Scienze Biologiche presso la Stanford University e un J.D. presso la George Washington University Law School.
Olema Pharmaceuticals (Nasdaq: OLMA) ha nombrado a Shawnte M. Mitchell, J.D. como Chief Legal Officer y Corporate Secretary. Mitchell aporta 20 años de experiencia en los sectores de la salud, las ciencias de la vida y la sostenibilidad. Anteriormente, se desempeñó como Chief Legal Officer en Genomatica y ocupó puestos ejecutivos en Zogenix y Aptevo Therapeutics.
Mitchell liderará la función legal de Olema mientras la empresa avanza en sus programas avanzados de palazestrant y en el programa OP-3136 KAT6 a través del desarrollo clínico. Su experiencia abarca cuestiones regulatorias, comerciales, de propiedad intelectual y de desarrollo empresarial. Mitchell tiene una licenciatura en Ciencias Biológicas de la Universidad de Stanford y un J.D. de la Facultad de Derecho de la Universidad George Washington.
올레마 제약회사 (Nasdaq: OLMA)는 쇼안트 M. 미첼, J.D.를 최고 법률 책임자 및 기업 비서로 임명했습니다. 미첼은 의료, 생명 과학 및 지속 가능성 산업에서 20년의 경험을 가지고 있습니다. 그녀는 이전에 제노마티카에서 최고 법률 책임자로 근무했으며, 조젠닉스와 아프테보 테라퓨틱스에서 경영직을 역임했습니다.
미첼은 올레마의 법률 기능을 이끌며, 회사가 후기 단계의 팔라제스트란트 프로그램과 OP-3136 KAT6 프로그램을 임상 개발로 발전시키는 데 도움을 줄 것입니다. 그녀의 전문 분야는 규제, 상업, 지적 재산 및 사업 개발 문제를 포함합니다. 미첼은 스탠포드 대학교에서 생물학 학사 학위를, 조지 워싱턴 대학교 법대에서 J.D.를 취득했습니다.
Olema Pharmaceuticals (Nasdaq: OLMA) a nommé Shawnte M. Mitchell, J.D. au poste de Chief Legal Officer et Corporate Secretary. Mitchell apporte 20 ans d'expérience dans les secteurs de la santé, des sciences de la vie et de la durabilité. Elle a précédemment occupé le poste de Chief Legal Officer chez Genomatica et a occupé des postes exécutifs chez Zogenix et Aptevo Therapeutics.
Mitchell dirigera la fonction juridique d'Olema alors que l'entreprise fait progresser ses programmes avancés de palazestrant et le programme OP-3136 KAT6 à travers le développement clinique. Son expertise couvre les questions réglementaires, commerciales, de propriété intellectuelle et de développement commercial. Mitchell est titulaire d'un B.S. en sciences biologiques de l'Université de Stanford et d'un J.D. de la George Washington University Law School.
Olema Pharmaceuticals (Nasdaq: OLMA) hat Shawnte M. Mitchell, J.D. zur Chief Legal Officer und Corporate Secretary ernannt. Mitchell bringt 20 Jahre Erfahrung in den Bereichen Gesundheitswesen, Lebenswissenschaften und Nachhaltigkeit mit. Zuvor war sie Chief Legal Officer bei Genomatica und hatte Führungspositionen bei Zogenix und Aptevo Therapeutics inne.
Mitchell wird die Rechtsabteilung von Olema leiten, während das Unternehmen seine späten palazestrant Programme und das OP-3136 KAT6 Programm durch die klinische Entwicklung vorantreibt. Ihr Fachwissen umfasst regulatorische, kommerzielle, geistige Eigentums- und Geschäftsentwicklungsthemen. Mitchell hat einen B.S. in Biologischen Wissenschaften von der Stanford University und einen J.D. von der George Washington University Law School.
- Strengthened executive team with experienced legal professional
- Addition of expertise in regulatory and commercial matters for clinical-stage programs
- Enhanced capabilities in intellectual property and business development
- None.
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary.
“We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “Her extensive experience in regulatory, commercial, intellectual property, and business development matters in the biotechnology industry will be invaluable to Olema as we execute against our strategic priorities.”
Ms. Mitchell is a seasoned business leader with 20 years of experience advising publicly traded and privately held companies in the healthcare, life sciences, and sustainability industries. She joins Olema from Genomatica, where she served as Chief Legal Officer and was responsible for overseeing significant business transformation initiatives, contract negotiations, and the implementation of company-wide compliance and environmental initiatives. Prior to this, Ms. Mitchell was Executive Vice President, General Counsel and Corporate Secretary at Zogenix, where she contributed to the development and execution of the company’s strategic and operational plans while overseeing compliance, governance, intellectual property, data privacy, and contractual matters. Before Zogenix, she served as Senior Vice President of Corporate Affairs, Chief Compliance Officer and Corporate Secretary at Aptevo Therapeutics, leading the company’s legal, intellectual property, compliance, and human resources functions. Ms. Mitchell currently serves as a member of the Board of Directors of Life Science Cares Bay Area and a member of How Women Lead’s Silicon Valley Board of Advisors. She received a B.S. in Biological Sciences from Stanford University and a J.D. from The George Washington University Law School.
“I am excited to join Olema as it approaches key milestones in its journey to deliver new treatment options to patients with breast cancer and beyond,” said Ms. Mitchell. “I look forward to contributing my unique skillset and expertise to support Olema’s growth as we develop novel therapies for endocrine-driven cancers.”
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What is Shawnte Mitchell's role at Olema Pharmaceuticals (OLMA)?
What programs is OLMA currently developing in clinical trials?
What is Shawnte Mitchell's professional background before joining OLMA?
What therapeutic areas does Olema Pharmaceuticals (OLMA) focus on?
